Healthcare [ 10/13 ] | Diagnostics & Research [ 102/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 23 | -0.41 Decreased by -36.67% | -0.48 Increased by +14.58% |
| Aug 7, 23 | -0.42 Decreased by -35.48% | -0.45 Increased by +6.67% |
| May 8, 23 | -0.4 Decreased by -29.03% | -0.44 Increased by +9.09% |
| Feb 23, 23 | -0.41 Decreased by -10.81% | -0.45 Increased by +8.89% |
| Nov 8, 22 | -0.3 Increased by +14.29% | -0.4 Increased by +25% |
| Aug 3, 22 | -0.31 Increased by +8.82% | -0.36 Increased by +13.89% |
| May 10, 22 | -0.31 Increased by +45.61% | -0.4 Increased by +22.5% |
| Feb 24, 22 | -0.37 Decreased by -23.33% | -0.36 Decreased by -2.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.28 M Decreased by -51.19% | -29.26 M Decreased by -37.83% | Decreased by -315.24% Decreased by -182.4% |
| Jun 30, 23 | 1.87 M Increased by +22.32% | -29.57 M Decreased by -77.38% | Decreased by -1.58 K% Decreased by -45.02% |
| Mar 31, 23 | 2.53 M Increased by +73.98% | -26.4 M Decreased by -51.12% | Decreased by -1.04 K% Increased by +13.14% |
| Dec 31, 22 | 7.75 M Increased by +416.52% | -33.29 M Decreased by -45.99% | Decreased by -429.4% Increased by +71.74% |
| Sep 30, 22 | 19.02 M Increased by +1.05 K% | -21.23 M Decreased by -0.4% | Decreased by -111.63% Increased by +91.24% |
| Jun 30, 22 | 1.53 M Decreased by -16.23% | -16.67 M Increased by +8.21% | Decreased by -1.09 K% Decreased by -9.57% |
| Mar 31, 22 | 1.45 M Decreased by -18.23% | -17.47 M Increased by +39.24% | Decreased by -1.2 K% Increased by +25.69% |
| Dec 31, 21 | 1.5 M Decreased by -5% | -22.8 M Decreased by -73.11% | Decreased by -1.52 K% Decreased by -82.22% |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.